Surgical Science Sweden Ab · OMXSTO:SUS

Surgical Science Sweden Ab — Q2 2025 Earnings Presentation

10 slides from Surgical Science Sweden Ab's earnings presentation, Aug 21, 2025

  1. Slide 1: Presentation of Interim Report Q2

    Presentation of Interim Report Q2 ©2025 Surgical Science. | All rights reserved.

  2. Slide 2: CEO comments – Q2 2025

    CEO comments – Q2 2025  Q2 saw a more negative development due to macroeconomic pressures  Net sales reached SEKm 209, a 2% decline vs Q2 2024 (+4% in local currencies)  Educational Products sales flat and weaker than expected, some of it related to timing effects ▫Backlog increased by SEKm 30 du

  3. Slide 3: Q2: Weak sales and large currency effects weighed on the result

    Q2: Weak sales and large currency effects weighed on the result SEKm Q2:  Net sales down 2% to SEKm 209.2 (112.1). In local currencies up 4%. SEKm 22.1 from IU.  Educational Products’ sales flat (-20% excl IU). Regions: EMEA (+22%), Asia (-40%), Americas (+15%).  Industry/OEM down 3%. License rev

  4. Slide 4: Revenue Streams

    REVENUE STREAMS SEKm  License rev’s: 28 (32) percent of total revenues. Lumpy for new entrants, revenues from several customers. Intuitive sales affected by lower subscription renewals on older generations.  Simulator sales down 8%.  Development rev’s high. Consists of both robotics’ projects and

  5. Slide 5: Costs and EBIT Margin Q2 2025

    COSTS AND EBIT MARGIN Q2 2025  Gross margin 65% (68). Weak simulator sales, lower license revenues, lower direct sales and inclusion of IU had a negative effect. Cost of goods sold 35% (32)  Sales: 28% (20) of sales. High activity in trade fairs and Sales costs 28% (20) congresses. Additional SEKm

  6. Slide 6: Organization

    ORGANIZATION No of employees at end of period: 327 (265) Men 232 (192) Women 95 (73) Israel 146 (136) Sweden 69 (57) Market presence >90 countries USA 58 (55) UK 35 (1) Other 18 (14) * Offices / Development sites * Other: Primarily Germany and China. ©2025 Surgical Science. | All rights reserved. 5

  7. Slide 7: Adjusted EBIT

    ADJUSTED EBIT Q2:  Adjusted EBIT SEKm -16.7 (39.5), margin -8% (15). YTD:  Adjusted EBIT SEKm 13.4 (71.5), margin 3% (18). Adjusted for acquisition and restructuring costs SEKm 40.0, margin 9%. ©2025 Surgical Science. | All rights reserved. 6

  8. Slide 8: Finance Net and Taxes

    FINANCE NET AND TAXES  Finance net for the quarter was SEKm 3.7 (4.4). Interest on bank balances, revaluation internal loans and IFRS 16 effect.  Tax expense for the quarter was SEKm -1.4 (-9.2).  Net result for the quarter was SEKm -20.1 (28.6). ©2025 Surgical Science. | All rights reserved. 7

  9. Slide 9: Cash Flow

    CASH FLOW  Cash flow from operating activities SEKm 16.2 (30.0). Larger supplementary tax payments made in Sweden. Change in working capital SEKm 20.0 (-17.1 ). Inventory increased while accounts receivable decreased.  Cash flow from investing activities SEKm -12.6 (-12.5) mainly investments in de

  10. Slide 10: Thank you

    Thank you Find out more at: www.surgicalscience.com Tom Englund, CEO tom.englund@surgicalscience.com Anna Ahlberg, CFO anna.ahlberg@surgicalscience.com ©2025 Surgical Science. | All rights reserved.

Surgical Science Sweden — Q2 2025 Earnings Presentation on 6ix